FIGURE 5 from Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity
Year: 2023
Type: other
Abstract: Release of immune suppression of endogenous TAA-specific CTLs from treated (Tumor 1) and untreated (Tumor 2) subcutaneous tumors mediated by Delta-24-RGDOX. PD-1 and TIM3 levels were assessed in CD8+ leukocytes (A), adoptive pmel-1 T cells (B) or endogenous OVA-targeting CTLs (C) from the indicated tumors. Top: Tumor 1; bottom: Tumor 2. A, Left: Representative flow cytometry histograms; Right: Quantification of MFI of PD-1 or TIM3. B and C, Quantification of MFI of PD-1 or TIM3. D and E, Representative flow cytometry dot plots to show relative amount of cell numbers and immune checkpoint protein (PD-1 and TIM3) expression levels between endogenous OVA-specific CTLs and CD8+ leukocytes (D) or OVA-specific CTLs and adoptive pmel-1 T cells (E) from the indicated tumors. Leukocytes from the tumors in the treatment groups as depicted in Fig. 3A were profiled with flow cytometry. Leukocytes were from grouped tissue (4 to 7 mice/group) and processed in triplicate. The columns in the graphs represent the mean ± SD (n = 3). RGDOX: Delta-24-RGDOX; T cells: pmel-1 T cells. ns, not significant (P > 0.05); **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Two-tailed Student t test.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4382240611